---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018145"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:47:37.824480+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024

## Summary
- Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.
- CEO John S. Yu receives 190,840 RSUs ($250K) and $87.5K cash bonus for FY2024.
- CSO Neil Bhomick gets 171,756 RSUs ($225K) and $50K cash bonus.
- CFO Doug Samuelson gets 152,672 RSUs ($200K) and $50K bonus; VP R&D Ramachandran Murali also gets 152,672 RSUs ($200K) and $40K.
- Independent directors Hyun Bae, Hansoo Keyoung, Rahul Singhvi each receive 19,084 RSUs worth $25K.

## SEC filing metadata
- accession: 0001493152-25-018145
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/0001493152-25-018145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018145
- JSON: https://secwatch.observer/filing/0001493152-25-018145.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.